Life after Lyxumia: Ex-Zealand CEO Solomon's next quest is to cure HIV
This article was originally published in Scrip
Executive Summary
David Horn Solomon spent six years heading up Zealand Pharma, developer of the GLP-1 agonist Lyxumia (lixisenatide), which has travelled a bumpy road in the hands of licensing partner Sanofi. He is now CEO of Bionor Pharma, a company that is hoping to make headway with its HIV vaccine. Rather a challenge, but Dr Solomon believes the company is a clear two years ahead of the competition and with his guidance stands a real chance of being the first to tackle the 'What's next?' question in the treatment of HIV.
You may also be interested in...
Akari Taps Zealand Ex-CEO Solomon To Reboot Tick-Based Group's Prospects
Struggling to restore investor confidence amid controversy, Akari has convinced former Zealand CEO David Solomon to take on the same role there and try to re-energize the NY-based biotech.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.